[Description of adverse events in publications of clinical trials: much room for improvement.]
Description of toxicity is crucial for a thorough evaluation of cancer treatments, but it is often suboptimal. A systematic review of target drugs and immunotherapy approved by Food and Drug Administration between 2000 and 2015 showed, for instance, that 95% of publications did not describe late toxicities, 94% did not report the duration of adverse events while, in 75% of papers, the list of toxicities was limited to the most frequent ones. The availability of online appendixes would make it possible not to limit the published information, improving the accuracy of the description of adverse events.